Article
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Scientific reports - 19 May 2021
Pham Nhu-An, Radulovich Nikolina, Ibrahimov Emin, Martins-Filho Sebastiao N, Li Quan, Pintilie Melania, Weiss Jessica, Raghavan Vibha, Cabanero Michael, Denroche Robert E, Wilson Julie M, Metran-Nascente Cristiane, Borgida Ayelet, Hutchinson Shawn, Dodd Anna, Begora Michael, Chadwick Dianne, Serra Stefano, Knox Jennifer J, Gallinger Steven, Hedley David W, Muthuswamy Lakshmi, Tsao Ming-Sound
Abstract excerpt
Patient-derived xenograft (PDX) and their xenograft-derived organoid (XDO) models that recapitulate the genotypic and phenotypic landscape of patient cancers could help to advance research and lead to improved clinical management. PDX models were established from 276 pancreato-duodenal and biliary cancer resections. Initial, passage 0 (P0) engraftment rates were 59% (118/199) for pancreatic, 86% (25/29) for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
